Bottom line: A new mutation was identified in 9 percent of relapsed cases of pediatric acute myeloid leukemia (AML) that may define a new subtype of the disease. While the researchers identified the ...
Bottom Line: A new mutation was identified in 9 percent of relapsed cases of pediatric acute myeloid leukemia (AML) that may define a new subtype of the disease. While the researchers identified the ...
Differences in the immune microenvironment between early and late-onset colon and rectal cancer. Feasibility and clinical impact of routine molecular testing of gastrointestinal (GI) cancers at a ...
Analysis of stage of melanoma diagnosis in relation to insurance type and income as indicator of early/late diagnosis. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This ...
Scientists have made a rare discovery that allows them to attribute two types of tumour almost entirely to specific mutations that lie in two related genes. These mutations are found in nearly 100 per ...
This is a preview. Log in through your library . Abstract To define mutations present in 23 exons and flanking intronic sequences of the cystic fibrosis transmembrane conductance regulator (CFTR) gene ...
Wild type and three abscisic acid (ABA)-insensitive mutants of Arabidopsis (ABI1, ABI2, and ABI3) were compared for their ability to respond to ABA for a variety of ABA-inducible responses throughout ...
A nonsense mutation is a genetic mutation in a DNA sequence that results in a shorter, unfinished protein product. DNA is a chain of many smaller molecules called nucleotides. During protein formation ...
Over a year into the coronavirus pandemic, fears no longer only surround the spread of the virus but also its new forms, or variants. These include B.1.1.7. from the U.K., which was detected in ...
A new approach to gene therapy for retinitis pigmentosa may help patients with advanced disease regain vision regardless of which genetic mutation is causing the condition. An optogenetic therapy ...
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase ...
In the version of this article initially published, the name of author Victoria Goody was misspelled, and the following statement was omitted from the Acknowledgments: “The EuroBoNeT consortium, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback